River Street Advisors LLC Has $608,000 Position in Stryker Co. (NYSE:SYK)

River Street Advisors LLC boosted its stake in Stryker Co. (NYSE:SYK) by 7.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,700 shares of the medical technology company’s stock after acquiring an additional 114 shares during the period. River Street Advisors LLC’s holdings in Stryker were worth $608,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Carnegie Capital Asset Management LLC boosted its holdings in Stryker by 0.5% in the fourth quarter. Carnegie Capital Asset Management LLC now owns 96,241 shares of the medical technology company’s stock valued at $28,820,000 after acquiring an additional 497 shares during the last quarter. Atlantic Edge Private Wealth Management LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $1,561,000. CoreCap Advisors LLC boosted its holdings in shares of Stryker by 3.9% during the 4th quarter. CoreCap Advisors LLC now owns 5,030 shares of the medical technology company’s stock worth $1,506,000 after buying an additional 191 shares in the last quarter. Consolidated Planning Corp bought a new position in shares of Stryker during the 4th quarter worth approximately $205,000. Finally, Meritage Portfolio Management bought a new position in shares of Stryker during the 4th quarter worth approximately $569,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

NYSE SYK traded up $0.51 during trading hours on Friday, hitting $340.25. The company had a trading volume of 1,894,420 shares, compared to its average volume of 1,082,587. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. Stryker Co. has a 52 week low of $249.98 and a 52 week high of $361.41. The firm has a market capitalization of $129.62 billion, a price-to-earnings ratio of 38.84, a PEG ratio of 2.68 and a beta of 0.92. The firm has a 50 day simple moving average of $337.38 and a 200 day simple moving average of $333.66.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.36 by $0.14. Stryker had a return on equity of 23.05% and a net margin of 16.03%. The firm had revenue of $5.24 billion for the quarter, compared to analysts’ expectations of $5.10 billion. During the same period in the previous year, the firm earned $2.14 earnings per share. The business’s revenue was up 9.7% compared to the same quarter last year. Equities research analysts expect that Stryker Co. will post 11.95 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be paid a dividend of $0.80 per share. The ex-dividend date is Friday, June 28th. This represents a $3.20 annualized dividend and a dividend yield of 0.94%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Analyst Ratings Changes

A number of equities analysts have issued reports on SYK shares. Piper Sandler increased their price target on Stryker from $375.00 to $380.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Royal Bank of Canada increased their target price on Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Needham & Company LLC upgraded Stryker from a “hold” rating to a “buy” rating and set a $392.00 target price on the stock in a report on Wednesday, May 22nd. BTIG Research increased their target price on Stryker from $366.00 to $369.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Finally, Stifel Nicolaus increased their target price on Stryker from $350.00 to $375.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $370.58.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.